70% of Breast Cancers and a Link to Prostate Cancer... Dr. Sean Bohen, President & CEO, Olema Oncology

This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.